Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
Details : DehydraTECH-liraglutide is an orally administered drug candidate , which is currently being investigated for the treatment of diabetes mellitus and obesity.
Product Name : DehydraTECH-liraglutide
Product Type : Peptide
Upfront Cash : Inapplicable
December 09, 2024
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Semaglutide
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide
Details : BNT24005 (semaglutide) is a sublingual film which delivers glucagon-like peptide-1 (GLP-1) receptor agonist indicated for type 2 diabetes.
Product Name : BNT24005
Product Type : Peptide
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : Semaglutide
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lexaria Study Shows DehydraTECH Outperforms Rybelsus® in Weight Control, Diabetes
Details : Oral DehydraTECH-technology processed liraglutide (GLP-1 agonist) is being investigated for obesity in comparison with Rybelsus (semaglutide).
Product Name : DehydraTECH-liraglutide
Product Type : Peptide
Upfront Cash : Inapplicable
November 20, 2024
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Liraglutide,Semaglutide
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
Details : Oral DehydraTECH-technology processed semaglutide and liraglutide (GLP-1 agonist) is being investigated for obesity.
Product Name : DehydraTECH-liraglutide
Product Type : Peptide
Upfront Cash : Inapplicable
October 24, 2024
Lead Product(s) : Liraglutide,Semaglutide
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
Details : DehydraTECH-Liraglutide (liraglutide) is a DehydraTECH-processed GLP-1 receptor agonist, which is being evaluated for the treatment of diabetes and weight loss.
Product Name : DehydraTECH-liraglutide
Product Type : Peptide
Upfront Cash : Inapplicable
October 22, 2024
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Breakthrough T1D
Deal Size : Undisclosed
Deal Type : Funding
Breakthrough T1D and Integrated Nano Partner To Develop T1D Therapy
Details : The company will advance INT's technology which employs multi-cargo LNP to deliver multiple antigens using mRNA, along with immune-modifying small molecules, to re-train the immune system in T1D.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 09, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Breakthrough T1D
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Positive Interim Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
Details : DehydraTECH-Liraglutide (liraglutide) is a DehydraTECH-processed GLP-1 receptor agonist, which is being evaluated for the treatment of diabetes and weight loss.
Product Name : DehydraTECH-Liraglutide
Product Type : Peptide
Upfront Cash : Inapplicable
August 22, 2024
Lead Product(s) : Liraglutide
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, AstraZeneca will explore the use of Sernova’s Cell Pouch System as a potential platform for integration with its development of the next wave of innovative cell therapies for various indications.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 05, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : TFC-039
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Wanbang Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Sirona Biochem Signs International Partnership Agreement with Wanbang Biopharmaceuticals
Details : Under the agreement, Wanbang obtained the rights to develop the SGLT2 inhibitor, TFC-039 as a diabetes treatment in China and Sirona retained the global rights. SGLT2 inhibitors provide an opportunity to treat inflicted animals with an oral medication.
Product Name : TFC-039
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 23, 2022
Lead Product(s) : TFC-039
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Wanbang Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The patent application, entitled “Use of Ketamine in the Treatment of Diabetes and Obesity,” identifies protein bindings and interactions with ketamine leading to the discovery of ketamine as a potential treatment for Type 2 diabetes and obesity.
Product Name : Ketarx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 27, 2021
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable